Published on
July 31, 2020
- 11:00 GMT
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
RHB-204 is a potential first-line oral treatment for pulmonary nontuberculous mycobacteria (NTM) infections, a rare disease with no FDA-approved first-line therapy -- The pivotal Phase 3 study aims to enroll 125 patients at 50 clinical sites across the U.S …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Media, Advertising & PR
...
